Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.

被引：2

作者：

Marquez-Rodas, Ivan

Dalle, Stephane

Castanon, Eduardo

Sanmamed, Miguel F.

Arance, Ana Maria

Cerezuela-Fuentes, Pablo

Huertas, Roberto Martin

Rodriguez-Moreno, Juan Francisco

Gonzalez-Cao, Maria

Munoz-Couselo, Eva

Martin-Liberal, Juan

Rodriguez-Abreu, Delvys

Alberich-Bayarri, Angel

Mayorga-Ruiz, Irene

Vila, Miguel Angel Molina

Roman, Ruth

Chaney, Marya F.

Lopez, Javier Sanchez

Macia, Sonia

Quintero, Marisol

机构：

[1] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[2] CIBERONC, Madrid, Spain

[3] Hosp Civils Lyon, Pierre Benite, France

[4] Clin Univ Navarra, Madrid, Spain

[5] Clin Univ Navarra, Dept Med Oncol, Pamplona, Spain

[6] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[7] Hosp Virgen de la Arrixaca, Med Oncol, Murcia, Spain

[8] Hosp Clin Barcelona, Barcelona, Spain

[9] Hosp Univ Sanchinarro Clara Campal, Madrid, Spain

[10] Quiron Dexeus Univ Hosp, Inst Oncol Dr Rosell, Barcelona, Spain

[11] Vall dHebron Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[12] Inst Catala Oncol, Barcelona, Spain

[13] Univ Las Palmas de Gran Canaria, Complejo Hosp Univ Insular Materno Infantil Gran, Las Palmas Gran Canaria, Spain

[14] Quibim, Valencia, Spain

[15] Pangaea Oncol, Barcelona, Spain

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Highlight Therapeut, Valencia, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS9586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9586

引用

页数：3